Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa
- PMID: 28291719
- DOI: 10.1016/j.jmii.2016.08.014
Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa
Abstract
Background: Pseudomonas aeruginosa is a Gram-negative opportunistic bacterium, which considered as a common cause of nosocomial infection and life-threatening complications in immunocompromized and cystic fibrosis patients. Here, we evaluate the protective effect of recombinant vaccines composed of outer membrane proteins OprF and OprI alone or in combination with flagellin B against mucoid and nonmucoid pseudomonas infection.
Methods: BALB/C mice were immunized subcutaneous using OprF and OprI with or without flagellin B and antibody titers were determined. Serum bactericidal and opsonophagocytosis activities of immunized and control sera were estimated against mucoid and nonmucoid pseudomonas strains. Lung tissue sections from immunized and nonimmunized mice were analyzed and the levels of peripheral neutrophils infiltration into the lung and tissue inflammation were scored.
Results: Subcutaneous immunization using OprF and OprI with or without flagellin B elicited higher antibody titers against OprF, OprI, and flagellin B. The produced antibodies successfully opsonized both mucoid and nonmucoid strains with subsequent activation of the terminal pathway of complement that enhances killing of nonmucoid strains via complement-mediated lysis. Furthermore, opsonized mucoid and nonmucoid strains showed enhanced opsonophagocytosis via human peripheral neutrophils, a mechanism that kills P. aeruginosa when complement mediated lysis is not effective especially with mucoid strains. Immunized mice also showed a significant prolonged survival time, lower bacteremia, and reduced lung damage when compared with control nonimmunized mice.
Conclusion: Our data showed that mice immunized with OprF/OprI or OprF/OprI and flagellin B are significantly protected from infection caused by mucoid and nonmucoid strains of P. aeruginosa.
Keywords: Pseudomonas aeruginosa; flagellin B; mucoid; nonmucoid; outer membrane proteins.
Copyright © 2017. Published by Elsevier B.V.
Similar articles
-
A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.Infect Immun. 2009 Jun;77(6):2356-66. doi: 10.1128/IAI.00054-09. Epub 2009 Apr 6. Infect Immun. 2009. PMID: 19349426 Free PMC article.
-
Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.Vaccine. 2009 Nov 12;27(48):6762-9. doi: 10.1016/j.vaccine.2009.08.080. Epub 2009 Sep 8. Vaccine. 2009. PMID: 19744586
-
[Production of hybrid protein OprF-OprL of Pseudomonas aeruginosa].Zh Mikrobiol Epidemiol Immunobiol. 2012 May-Jun;(3):35-43. Zh Mikrobiol Epidemiol Immunobiol. 2012. PMID: 22830272 Russian.
-
Pseudomonas aeruginosa antigens as potential vaccines.FEMS Microbiol Rev. 1997 Nov;21(3):243-77. doi: 10.1111/j.1574-6976.1997.tb00353.x. FEMS Microbiol Rev. 1997. PMID: 9451816 Review.
-
Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: experimental studies in animals.APMIS Suppl. 1996;63:5-42. doi: 10.1111/j.1600-0463.1996.tb05581.x. APMIS Suppl. 1996. PMID: 8944052 Review.
Cited by
-
Multidrug Efflux Pumps and the Two-Faced Janus of Substrates and Inhibitors.Acc Chem Res. 2021 Feb 16;54(4):930-939. doi: 10.1021/acs.accounts.0c00843. Epub 2021 Feb 4. Acc Chem Res. 2021. PMID: 33539084 Free PMC article.
-
Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.Biomolecules. 2021 Jun 15;11(6):892. doi: 10.3390/biom11060892. Biomolecules. 2021. PMID: 34203937 Free PMC article. Review.
-
Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.Cells. 2020 Dec 5;9(12):2617. doi: 10.3390/cells9122617. Cells. 2020. PMID: 33291484 Free PMC article. Review.
-
Pseudomonas aeruginosa: Infections and novel approaches to treatment "Knowing the enemy" the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment.Infect Med (Beijing). 2023 May 26;2(3):178-194. doi: 10.1016/j.imj.2023.05.003. eCollection 2023 Sep. Infect Med (Beijing). 2023. PMID: 38073886 Free PMC article. Review.
-
A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection.NPJ Vaccines. 2023 Mar 14;8(1):37. doi: 10.1038/s41541-023-00618-w. NPJ Vaccines. 2023. PMID: 36918600 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical